AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s Disease drug development. We are developing innovative therapeutics with “best in class” potential against Alzheimer´s Disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody crenezumab for passive immunization is partnered with Genentech and has been selected for the first groundbreaking Alzheimer's prevention trial. We continue to develop in house the vaccine ACI-24 . These two programs in clinical development are focused on Alzheimer’s Disease and are backed by a rich portfolio of preclinical compounds. A preclinical stage anti-Tau antibody is partnered with Genentech. Our therapeutic molecules are also leveraged for Alzheimer´s Disease diagnostic and other central nervous system (CNS) and non-CNS diseases, such as Glaucoma.
Since its foundation in 2003, the company has raised CHF 64 million from private investors. Two out-licensing agreements with Genentech were closed in 2006 and 2012 for potential values of more than US$ 300 million and more than CHF 400 million respectively. Our team of 50 professionals is based on the site of the Ecole Polytechnique Federale (EPFL) in Lausanne, Switzerland.